Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theriva BiologicsTOVX -2.27%26 Debt-to-EBITDA is -0.44 as of Mar. 2026. GuruFocus rates TOVX with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 298 Biotechnology companies, Theriva Biologics ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Theriva Biologics's Debt-to-EBITDA or its related term are showing as below:
TOVX'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.17 Med: -0.08 Max: -0.05
Current: -0.17
During the past 13 years, the highest Debt-to-EBITDA Ratio of Theriva Biologics was -0.05. The lowest was -0.17. And the median was -0.08.
TOVX's Debt-to-EBITDA is ranked worse than 100% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs TOVX: -0.17
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Theriva Biologics Debt-to-EBITDA Related Terms
Theriva Biologics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Theriva Biologics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOVX vs BIVI, BCLI, LNAI: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Theriva Biologics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theriva Biologics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theriva Biologics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Theriva Biologics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Theriva Biologics (TOVX) has a Debt-to-EBITDA of -0.44 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Theriva Biologics. According to the industry distribution chart, Theriva Biologics ranks #999999 out of 298 companies in the Biotechnology industry.
Is Theriva Biologics' Debt-to-EBITDA too high?
Theriva Biologics' current Debt-to-EBITDA is -0.44. Based on the distribution chart, Theriva Biologics ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Theriva Biologics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Theriva Biologics' Debt-to-EBITDA compare to BIVI and BCLI?
According to the Biotechnology industry distribution chart, Theriva Biologics ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Theriva Biologics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Theriva Biologics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theriva Biologics's current Debt-to-EBITDA is -0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theriva Biologics stock overvalued right now?
Theriva Biologics (TOVX) has a current Debt-to-EBITDA of -0.44. The current Debt-to-EBITDA is -0.44. Theriva Biologics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Theriva Biologics (TOVX), the current Debt-to-EBITDA is -0.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
26GF Score
Get the complete analysis for TOVX
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TOVX has been successfully added to your 
